3957 POINT EDEN WAY, HAYWARD, CA
Changes in Board, Management or Compensation
Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Investor Presentation
Amended material disclosure
News
News, Underwriting Agreement, Legal Opinion
FY 2024
Q3
Q2
Q1
Amended Annual Report
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Additional Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Specialized Disclosure Report
Amended Schedule 13D - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload